Overview

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to determine the effects of 16 weeks of adjunctive pramlintide or exenatide use on glycemic control in Type 1 Diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Einstein College of Medicine
Baylor College of Medicine
Collaborators:
Albert Einstein College of Medicine of Yeshiva University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Exenatide
Insulin
Insulin, Globin Zinc
Islet Amyloid Polypeptide
Pramlintide